Cargando…

Prognostic value of programmed death ligand 1 (PD-L1) in glioblastoma: a systematic review, meta-analysis and validation based on dataset

Excellent prognostic value of programmed death ligand 1 (PD-L1) is observed in patients with other cancers; however, the prognostic value of PD-L1 in glioblastoma (GBM) remains unclear. Therefore, this meta-analysis evaluated the prognostic value of PD-L1 in GBM. We performed a systematic search in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Huan, Xiao, Youchao, Ren, Xingguang, Wan, Dahai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809998/ https://www.ncbi.nlm.nih.gov/pubmed/34903133 http://dx.doi.org/10.1080/21655979.2021.1996515

Ejemplares similares

The Prognostic Value of Plasma Programmed Death Protein-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) in Patients with Gastrointestinal Stromal Tumor
por: Brinch, Charlotte Margareta, et al.
Publicado: (2022)

Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma
por: Zhu, Jun, et al.
Publicado: (2017)

Prognostic Value of BRAF, Programmed Cell Death 1 (PD1), and PD Ligand 1 (PDL1) Protein Expression in Colon Adenocarcinoma
por: Ibrahiem, Afaf T., et al.
Publicado: (2023)

Prognostic Value of Programmed Cell Death 1 Ligand-1 (PD-L1) or PD-1 Expression in Patients with Osteosarcoma: A Meta-Analysis
por: Huang, Xin, et al.
Publicado: (2018)

Prognostic value of programmed cell death ligand 1 (PD-L1) for hepatocellular carcinoma: a meta-analysis
por: Li, Xiao-Song, et al.
Publicado: (2020)

The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma
por: Chang, Boyang, et al.
Publicado: (2018)

Prognostic value of programmed death-ligand 1 in sarcoma: a meta-analysis
por: Zhu, Zhenhua, et al.
Publicado: (2017)

Clinicopathologic Significance and Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) in Patients With Hepatocellular Carcinoma: A Meta-Analysis
por: Li, Jing-Hua, et al.
Publicado: (2018)

Programmed Death 1 (PD-1) and PD-1 Ligand (PD-L1) Expression in Chronic Apical Periodontitis
por: Delgado, Ronan Jacques Rezende, et al.
Publicado: (2019)

Programmed Death Ligand-1 (PD-L1) Is an Independent Negative Prognosticator in Western-World Gallbladder Cancer
por: Albrecht, Thomas, et al.
Publicado: (2021)

In vitro Interactions of Chicken Programmed Cell Death 1 (PD-1) and PD-1 Ligand-1 (PD-L1)
por: Reddy, Vishwanatha R. A. P., et al.
Publicado: (2019)

Prognostic Significance of Programmed Cell Death 1 (PD-1) or PD-1 Ligand 1 (PD-L1) Expression in Epithelial-Originated Cancer: A Meta-Analysis
por: Zhang, Yaxiong, et al.
Publicado: (2015)

The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort
por: Ness, Nora, et al.
Publicado: (2017)

Immunohistochemical expression of programmed death-ligand 1 and CD8 in glioblastomas
por: El Samman, Dina Mohamed, et al.
Publicado: (2021)

Programmed Death Ligand 1 (PD-L1) Expression in Primary Angiosarcoma
por: Botti, Gerardo, et al.
Publicado: (2017)

Programmed death ligand 1 (PD-L1) expression in parathyroid tumors
por: Pan, Boju, et al.
Publicado: (2019)

Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer
por: Li, Yaqi, et al.
Publicado: (2016)

Association Between Activation of the Programmed Cell Death-1 (PD-1)/Programmed Death-Ligand 1 (PD-L1) Pathway and Pain in Patients with Cancer
por: Zhang, Jian, et al.
Publicado: (2019)

Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors
por: Song, Joon Seon, et al.
Publicado: (2019)

Implementation of programmed death-ligand 1 (PD-L1) expression as a prognostic biomarker for patients with lung cancer
por: Li, Huijuan, et al.
Publicado: (2022)

Prognostic and Clinicopathological Value of Programmed Death Ligand-1 in Breast Cancer: A Meta-Analysis
por: Guo, Yawen, et al.
Publicado: (2016)

Prognostic value of programmed death‐ligand 1 expression in patients with stage III colorectal cancer
por: Koganemaru, Shigehiro, et al.
Publicado: (2017)

The Prognostic Value of Circulating Soluble Programmed Death Ligand-1 in Cancers: A Meta-Analysis
por: Huang, Pei, et al.
Publicado: (2021)

Prognostic value of programmed death-ligand 1 status in Japanese patients with renal cell carcinoma
por: Uemura, Motohide, et al.
Publicado: (2021)

Prognostic Value of Galectin-9 Relates to Programmed Death-Ligand 1 in Patients With Multiple Myeloma
por: Lee, Byung-Hyun, et al.
Publicado: (2021)

Distinct prognostic values of programmed death-ligand 1 and programmed cell death protein 1 in lung adenocarcinoma and squamous cell carcinoma patients
por: Wang, Shuo, et al.
Publicado: (2021)

Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer
por: Bari, Shahla, et al.
Publicado: (2019)

Soluble programmed death-1 (sPD-1) and programmed death ligand 1 (sPD-L1) as potential biomarkers for the diagnosis and prognosis of glioma patients
por: Liu, Shujun, et al.
Publicado: (2020)

Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics
por: Abaza, Abdelrahman, et al.
Publicado: (2023)

Programmed death-ligand 1 (PD-L1) expression in various tumor types
por: Grosso, Joseph, et al.
Publicado: (2013)

Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer
por: Núñez Abad, Martín, et al.
Publicado: (2022)

Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value
por: Kim, Ahrong, et al.
Publicado: (2017)

Corrigendum to “Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer”
por: Bari, Shahla, et al.
Publicado: (2019)

2241. Outcomes of Program Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer
por: Bari, Shahla, et al.
Publicado: (2018)

Lenvatinib/Pembrolizumab as second line treatment for advanced melanoma patients refractory to programmed death 1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors
por: Ferrucci, Pier Francesco
Publicado: (2023)

The interaction between the soluble programmed death ligand-1 (sPD-L1) and PD-1(+) regulator B cells mediates immunosuppression in triple-negative breast cancer
por: Li, Xuejiao, et al.
Publicado: (2022)

Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value
por: Miglietta, Federica, et al.
Publicado: (2019)

Prognostic value of programmed cell death ligand-1 expression in ovarian cancer: an updated meta-analysis
por: Piao, Jinlan, et al.
Publicado: (2020)

Correction to: Prognostic value of programmed death-ligand 1 status in Japanese patients with renal cell carcinoma
por: Uemura, Motohide, et al.
Publicado: (2021)

Prognostic value of programmed cell death ligand-1 expression in breast cancer: A meta-analysis
por: Zhang, Yingzi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ga2kovkj04uk00j926ieg9seea